The city of Sacramento, California, currently has 6 active clinical trials seeking participants for Alzheimer's Disease research studies.
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Recruiting
In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. Clinicians use the C... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/18/2024
Locations: Sutter Institute for Medical Research, Sacramento, California
Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
06/17/2024
Locations: Option Care - Sacramento, Sacramento, California +1 locations
Conditions: Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/13/2024
Locations: Local Institution - 0209, Sacramento, California
Conditions: Alzheimer Disease, Early Onset
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/06/2024
Locations: Sutter Health's Palo Alto Medical Foundation, Sacramento, California
Conditions: Alzheimer Disease
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
Recruiting
This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.
Gender:
All
Ages:
All
Trial Updated:
05/01/2024
Locations: Sutter Health, Sacramento, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease
Senicapoc in Alzheimer's Disease
Recruiting
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Co... Read More
Gender:
All
Ages:
Between 55 years and 85 years
Trial Updated:
04/19/2024
Locations: University of California, Davis Alzheimer's Disease Center, Sacramento, California
Conditions: Mild Cognitive Impairment, Alzheimer Disease